[1]
|
United Nations: Department of Economic and Social Affairs, Population Division (2019) World Population Prospects 2019: Highlights (ST/ESA/SER.A/423) United Nations New York: Available from: https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf.
|
[2]
|
United Nations: Department of Economic and Social Affairs Population Dynamics World Population Prospects 2019 Available from: https://population.un.org/wpp/DataQuery/.
|
[3]
|
Bektas A, Schurman SH, Sen R, et al. (2017) Human T cell immunosenescence and inflammation in aging. J Leukoc Biol 102: 977-988. doi: 10.1189/jlb.3RI0716-335R
|
[4]
|
Austad SN, Hoffman JM (2018) Is antagonistic pleiotropy ubiquitous in aging biology? Evol Med Public Hlth 2018: 287-294. doi: 10.1093/emph/eoy033
|
[5]
|
Fülöp T, Larbi A, Witkowski JM (2019) Human Inflammaging. Gerontology 65: 495-504. doi: 10.1159/000497375
|
[6]
|
Pinti M, Appay V, Campisi J, et al. (2016) Aging of the immune system: Focus on inflammation and vaccination. Eur J Immunol 46: 2286-2301. doi: 10.1002/eji.201546178
|
[7]
|
Oh SJ, Lee JK, Shin OS (2019) Aging and the Immune System: The Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. Immune Netw 19: e37. doi: 10.4110/in.2019.19.e37
|
[8]
|
Crooke SN, Ovsyannikova IG, Poland GA, et al. (2019) Immunosenescence and human vaccine immune responses. Immun Ageing 16: 25. doi: 10.1186/s12979-019-0164-9
|
[9]
|
World Health Organization COVID-19 vaccines Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines.
|
[10]
|
Center for Disease Control and Prevention Weekly Updates by Select Demographic and Geographic Characteristics Available from: https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#AgeAndSex.
|
[11]
|
Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. (2007) The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25: 5086-5096. doi: 10.1016/j.vaccine.2007.03.046
|
[12]
|
Gralinski LE, Menachery VD (2020) Return of the Coronavirus: 2019-nCoV. Viruses 12: 135. doi: 10.3390/v12020135
|
[13]
|
Cianci R, Franza L, Massaro MG, et al. (2020) The Interplay between Immunosenescence and Microbiota in the Efficacy of Vaccines. Vaccines (Basel) 8: 636. doi: 10.3390/vaccines8040636
|
[14]
|
Zhang Y, Zeng G, Pan H, et al. (2020) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis S1473–3099: 30987.
|
[15]
|
Xia S, Zhang Y, Wang Y, et al. (2020) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 21: 39-51. doi: 10.1016/S1473-3099(20)30831-8
|
[16]
|
Thompson HL, Smithey MJ, Surh CD, et al. (2020) Functional and Homeostatic Impact of Age-Related Changes in Lymph Node Stroma. Front Immunol 8: 706. doi: 10.3389/fimmu.2017.00706
|
[17]
|
Song CY, Xu J, He JQ, et al. (2020) Immune dysfunction following COVID-19, especially in severe patients. Sci Rep 10: 15838. doi: 10.1038/s41598-020-72718-9
|
[18]
|
Connors J, Bell MR, Marcy J, et al. (2021) The impact of immuno-aging on SARS-CoV-2 vaccine development. Geroscience 43: 31-51. doi: 10.1007/s11357-021-00323-3
|
[19]
|
Arvey A, Rowe M, Legutki JB, et al. (2020) Age-associated changes in the circulating human antibody repertoire are upregulated in autoimmunity. Immun Ageing 17: 28. doi: 10.1186/s12979-020-00193-x
|
[20]
|
Frawley T, van Gelderen F, Somanadhan S, et al. (2020) The impact of COVID-19 on health systems, mental health and the potential for nursing. Ir J Psychol Med 16: 1-7. doi: 10.1017/ipm.2020.105
|
[21]
|
Ponnappan S, Ponnappan U (2011) Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal 14: 1551-1585. doi: 10.1089/ars.2010.3228
|
[22]
|
Solana R, Pawelec G, Tarazona R (2006) Aging and innate immunity. Immunity 24: 491-494. doi: 10.1016/j.immuni.2006.05.003
|
[23]
|
Ferrucci L, Fabbri E (2018) Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15: 505-522. doi: 10.1038/s41569-018-0064-2
|
[24]
|
Gubbels Bupp MR, Potluri T, Fink AL, et al. (2018) The Confluence of Sex Hormones and Aging on Immunity. Front Immunol 9: 1269. doi: 10.3389/fimmu.2018.01269
|
[25]
|
van Eeden C, Khan L, Osman MS, et al. (2020) Natural Killer Cell Dysfunction and Its Role in COVID-19. Int J Mol Sci 21: 6351. doi: 10.3390/ijms21176351
|
[26]
|
Przemska-Kosicka A, Childs CE, Maidens C, et al. (2018) Age-Related Changes in the Natural Killer Cell Response to Seasonal Influenza Vaccination Are Not Influenced by a Synbiotic: a Randomised Controlled Trial. Front Immunol 9: 591. doi: 10.3389/fimmu.2018.00591
|
[27]
|
Guo H, Kumar P, Moran TM, et al. (2009) The functional impairment of natural killer cells during influenza virus infection. Immunol Cell Biol 87: 579-589. doi: 10.1038/icb.2009.60
|
[28]
|
Fulop T, Witkowski JM, Le Page A, et al. (2017) Intracellular signalling pathways: targets to reverse immunosenescence. Clin Exp Immunol 187: 35-43. doi: 10.1111/cei.12836
|
[29]
|
Zhou R, To KK, Wong YC, et al. (2020) Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity 53: 864-877. doi: 10.1016/j.immuni.2020.07.026
|
[30]
|
Fulop T, Larbi A, Dupuis G, et al. (2018) Immunosenescence and Inflamm-Aging as Two Sides of the Same Coin: Friends or Foes? Front Immunol 8: 1960. doi: 10.3389/fimmu.2017.01960
|
[31]
|
Iberg CA, Jones A, Hawiger D (2017) Dendritic Cells As Inducers of Peripheral Tolerance. Trends Immunol 38: 793-804. doi: 10.1016/j.it.2017.07.007
|
[32]
|
Ray D, Yung R (2018) Immune senescence, epigenetics and autoimmunity. Clin Immunol 196: 59-63. doi: 10.1016/j.clim.2018.04.002
|
[33]
|
Agrawal A, Sridharan A, Prakash S, et al. (2012) Dendritic cells and aging: consequences for autoimmunity. Expert Rev Clin Immunol 8: 73-80. doi: 10.1586/eci.11.77
|
[34]
|
Agrawal A, Agrawal S, Gupta S (2017) Role of Dendritic Cells in Inflammation and Loss of Tolerance in the Elderly. Front Immunol 8: 896. doi: 10.3389/fimmu.2017.00896
|
[35]
|
Agrawal A, Agrawal S, Gupta S (2018) Role of Dendritic Cells in Aging. Handbook of Immunosenescence Cham: Springer.
|
[36]
|
Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. (2020) Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 181: 1036-1045. doi: 10.1016/j.cell.2020.04.026
|
[37]
|
Schröder AK, Rink L (2003) Neutrophil immunity of the elderly. Mech Ageing Dev 124: 419-425. doi: 10.1016/S0047-6374(03)00017-4
|
[38]
|
Butcher S, Chahel H, Lord JM (2000) Review article: ageing and the neutrophil: no appetite for killing? Immunology 100: 411-416. doi: 10.1046/j.1365-2567.2000.00079.x
|
[39]
|
Naccache PH, Lefebvre JS (2014) A straight neutrophil path to healthy aging? Blood 123: 154-156. doi: 10.1182/blood-2013-11-538256
|
[40]
|
Mócsai A (2013) Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med 210: 1283-1299. doi: 10.1084/jem.20122220
|
[41]
|
Dinauer MC (2014) Disorders of neutrophil function: an overview. Methods Mol Biol 1124: 501-515. doi: 10.1007/978-1-62703-845-4_30
|
[42]
|
Ferrucci L, Fabbri E (2018) Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15: 505-522. doi: 10.1038/s41569-018-0064-2
|
[43]
|
Aiello A, Farzaneh F, Candore G, et al. (2019) Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Front Immunol 10: 2247. doi: 10.3389/fimmu.2019.02247
|
[44]
|
Rubtsov AV, Rubtsova K, Fischer A, et al. (2011) Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity. Blood 118: 1305-1315. doi: 10.1182/blood-2011-01-331462
|
[45]
|
Bektas A, Schurman SH, Sen R, et al. (2017) Human T cell immunosenescence and inflammation in aging. J Leukoc Biol 102: 977-988. doi: 10.1189/jlb.3RI0716-335R
|
[46]
|
Tu W, Rao S (2016) Mechanisms Underlying T Cell Immunosenescence: Aging and Cytomegalovirus Infection. Front Microbiol 7: 2111.
|
[47]
|
Gustafson CE, Kim C, Weyand CM, et al. (2020) Influence of immune aging on vaccine responses. J Allergy Clin Immunol 145: 1309-1321. doi: 10.1016/j.jaci.2020.03.017
|
[48]
|
Park S, Nahm MH (2011) Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun 79: 314-320. doi: 10.1128/IAI.00768-10
|
[49]
|
Zhu FC, Guan XH, Li YH, et al. (2020) Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396: 479-488. doi: 10.1016/S0140-6736(20)31605-6
|
[50]
|
Schenkelberg T (2020) Vaccine-induced protection in aging adults and pandemic response. Biochem Biophys Res Commun S0006-291X(20)32020-9.
|
[51]
|
Ruan Q, Yang K, Wang W, et al. (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46: 846-848. doi: 10.1007/s00134-020-05991-x
|
[52]
|
McElhaney JE, Coler RN, Baldwin SL (2013) Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev Vaccines 12: 759-766. doi: 10.1586/14760584.2013.811193
|
[53]
|
Huff WX, Kwon JH, Henriquez M, et al. (2019) The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology. Int J Mol Sci 20: 2810. doi: 10.3390/ijms20112810
|
[54]
|
McElhaney JE, Verschoor CP, Andrew MK, et al. (2020) The immune response to influenza in older humans: beyond immune senescence. Immun Ageing 17: 10. doi: 10.1186/s12979-020-00181-1
|
[55]
|
Saletti G, Gerlach T, Jansen JM, et al. (2020) Older adults lack SARS CoV-2 cross-reactive T-lymphocytes directed to human coronaviruses OC43 and NL63. Sci Rep 10: 21447. doi: 10.1038/s41598-020-78506-9
|
[56]
|
Ma S, Wang C, Mao X, et al. (2019) B Cell Dysfunction Associated with Aging and Autoimmune Diseases. Front Immunol 10: 318. doi: 10.3389/fimmu.2019.00318
|
[57]
|
Cancro MP, Hao Y, Scholz JL, et al. (2009) B cells and aging: molecules and mechanisms. Trends Immunol 30: 313-318. doi: 10.1016/j.it.2009.04.005
|
[58]
|
Phalke S, Marrack P (2018) Age (autoimmunity) associated B cells (ABCs) and their relatives. Curr Opin Immunol 55: 75-80. doi: 10.1016/j.coi.2018.09.007
|
[59]
|
Bulati M, Caruso C, Colonna-Romano G (2017) From lymphopoiesis to plasma cells differentiation, the age-related modifications of B cell compartment are influenced by “inflamm-ageing”. Ageing Res Rev 36: 125-136. doi: 10.1016/j.arr.2017.04.001
|
[60]
|
Du SW, Arkatkar T, Jacobs HM, et al. (2019) Generation of functional murine CD11c+ age-associated B cells in the absence of B cell T-bet expression. Eur J Immunol 49: 170-178. doi: 10.1002/eji.201847641
|
[61]
|
Du SW, Arkatkar T, Al Qureshah F, et al. (2019) Functional Characterization of CD11c+ Age-Associated B Cells as Memory B Cells. J Immunol 203: 2817-2826. doi: 10.4049/jimmunol.1900404
|
[62]
|
Karnell JL, Kumar V, Wang J, et al. (2017) Role of CD11c+ T-bet+ B cells in human health and disease. Cell Immunol 321: 40-45. doi: 10.1016/j.cellimm.2017.05.008
|
[63]
|
Sachinidis A, Xanthopoulos K, Garyfallos A (2020) Age-Associated B Cells (ABCs) in the Prognosis, Diagnosis and Therapy of Systemic Lupus Erythematosus (SLE). Mediterr J Rheumatol 31: 311-318. doi: 10.31138/mjr.31.3.311
|
[64]
|
Hartley GE, Edwards ESJ, Aui PM, et al. (2020) Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol 5: eabf8891. doi: 10.1126/sciimmunol.abf8891
|
[65]
|
Cañete PF, Vinuesa CG (2020) COVID-19 Makes B Cells Forget, but T Cells Remember. Cell 183: 13-15. doi: 10.1016/j.cell.2020.09.013
|
[66]
|
Sosa-Hernández VA, Torres-Ruíz J, Cervantes-Díaz R, et al. (2020) B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients. Front Immunol 11: 611004. doi: 10.3389/fimmu.2020.611004
|
[67]
|
Hao Y, O'Neill P, Naradikian MS, et al. (2011) A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood 118: 1294-304. doi: 10.1182/blood-2011-01-330530
|
[68]
|
Park S, Nahm MH (2011) Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun 79: 314-320. doi: 10.1128/IAI.00768-10
|
[69]
|
Smetana J, Chlibek R, Shaw J, et al. (2018) Influenza vaccination in the elderly. Hum Vaccin Immunother 14: 540-549. doi: 10.1080/21645515.2017.1343226
|
[70]
|
Kwong JC, Campitelli MA, Gubbay JB, et al. (2013) Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season. Clin Infect Dis 57: 820-827. doi: 10.1093/cid/cit404
|
[71]
|
Bonmarin I, Belchior E, Lévy-Bruhl D (2015) Impact of influenza vaccination on mortality in the French elderly population during the 2000–2009 period. Vaccine 33: 1099-1101. doi: 10.1016/j.vaccine.2015.01.023
|
[72]
|
Chiu C (2016) Seasonal influenza vaccines and hurdles to mutual protection. Clin Microbiol Infect 22: S113-S119. doi: 10.1016/j.cmi.2016.03.021
|
[73]
|
Koldaş ZL (2017) Yaşlı popülasyonda bağışıklama (aşılama) [Vaccination in the elderly population]. Turk Kardiyol Dern Ars 45: 124-127.
|
[74]
|
Derhovanessian E, Pawelec G (2012) Vaccination in the elderly. Microb Biotechnol 5: 226-232. doi: 10.1111/j.1751-7915.2011.00283.x
|
[75]
|
World Health Organization The COVID-19 candidate vaccine landscape and tracker Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
|
[76]
|
World Health Organization COVID-19 vaccines Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines?.
|
[77]
|
Precision vaccinations EpiVacCorona Vaccine Available from: https://www.precisionvaccinations.com/vaccines/epivaccorona-vaccine.
|
[78]
|
Novavax Coronavirus Vaccine Candidate Updates Available from: https://www.novavax.com/covid-19-coronavirus-vaccine-candidate-updates.
|
[79]
|
Keech C, Albert G, Cho I, et al. (2020) Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med 383: 2320-2332. doi: 10.1056/NEJMoa2026920
|
[80]
|
Dai L, Gao GF (2020) Viral targets for vaccines against COVID-19. Nat Rev Immunol 18: 1-10.
|
[81]
|
Balakrishnan VS (2020) The arrival of Sputnik V. Lancet Infect Dis 20: 1128. doi: 10.1016/S1473-3099(20)30709-X
|
[82]
|
Sputnik V GENERAL INFORMATION Available from: https://sputnikvaccine.com/rus/about-vaccine/.
|
[83]
|
Johnson & Johnson Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate Available from: https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate.
|
[84]
|
Knoll MD, Wonodi C (2020) Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet S0140-6736(20)32623-4.
|
[85]
|
Tanne JH (2020) Covid-19: Pfizer-BioNTech vaccine is rolled out in US. BMJ 371: m4836. doi: 10.1136/bmj.m4836
|
[86]
|
Centers for Disease Control and Prevention (CDC) Moderna COVID-19 Vaccine Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html.
|
[87]
|
BioRender COVID-19 Vaccine & Therapeutics Tracker Available from: https://biorender.com/covid-vaccine-tracker.
|
[88]
|
Coelingh K, Olajide IR, MacDonald P, et al. (2015) Efficacy and effectiveness of live attenuated influenza vaccine in school-age children. Expert Rev Vaccines 14: 1331-1346. doi: 10.1586/14760584.2015.1078732
|
[89]
|
Singanayagam A, Zambon M, Lalvani A, et al. (2018) Urgent challenges in implementing live attenuated influenza vaccine. Lancet Infect Dis 18: e25-e32. doi: 10.1016/S1473-3099(17)30360-2
|
[90]
|
Chua BY, Sekiya T, Jackson DC (2018) Opinion: Making Inactivated and Subunit-Based Vaccines Work. Viral Immunol 31: 150-158. doi: 10.1089/vim.2017.0146
|
[91]
|
Brickley EB, Wright PF (2017) Maximising the impact of inactivated polio vaccines. Lancet Infect Dis 17: 680-681. doi: 10.1016/S1473-3099(17)30236-0
|
[92]
|
Tripathi NK, Shrivastava A (2018) Recent Developments in Recombinant Protein-Based Dengue Vaccines. Front Immunol 9: 1919. doi: 10.3389/fimmu.2018.01919
|
[93]
|
de Vries RD, Rimmelzwaan GF (2016) Viral vector-based influenza vaccines. Hum Vaccin Immunother 12: 2881-2901. doi: 10.1080/21645515.2016.1210729
|
[94]
|
Logunov DY, Dolzhikova IV, Zubkova OV, et al. (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396: 887-897. doi: 10.1016/S0140-6736(20)31866-3
|
[95]
|
Humphreys IR, Sebastian S (2018) Novel viral vectors in infectious diseases. Immunology 153: 1-9. doi: 10.1111/imm.12829
|
[96]
|
Dalmo RA (2018) DNA vaccines for fish: Review and perspectives on correlates of protection. J Fish Dis 41: 1-9. doi: 10.1111/jfd.12727
|
[97]
|
Tanne JH (2020) Covid-19: Pfizer-BioNTech vaccine is rolled out in US. BMJ 371: m4836. doi: 10.1136/bmj.m4836
|
[98]
|
Lundstrom K (2020) Self-Amplifying RNA Viruses as RNA Vaccines. Int J Mol Sci 21: 5130. doi: 10.3390/ijms21145130
|
[99]
|
Dong Y, Dai T, Wei Y, et al. (2020) A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther 5: 237. doi: 10.1038/s41392-020-00352-y
|
[100]
|
Armengaud J, Delaunay-Moisan A, Thuret JY, et al. (2020) The importance of naturally attenuated SARS-CoV-2 in the fight against COVID-19. Environ Microbiol 22: 1997-2000. doi: 10.1111/1462-2920.15039
|
[101]
|
Alsulaiman JW, Khasawneh AI, Kheirallah KA (2020) Could “trained immunity” be induced by live attenuated vaccines protect against COVID-19? Review of available evidence. J Infect Dev Ctries 14: 957-962. doi: 10.3855/jidc.12805
|
[102]
|
Fidel PL, Noverr MC (2020) Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection? mBio 11: e00907-e00920.
|
[103]
|
Roukens AH, Soonawala D, Joosten SA, et al. (2011) Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One 6: e27753. doi: 10.1371/journal.pone.0027753
|
[104]
|
Monath TP, Cetron MS, McCarthy K, et al. (2005) Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 1: 207-214. doi: 10.4161/hv.1.5.2221
|
[105]
|
Al-Kassmy J, Pedersen J, Kobinger G (2020) Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? Viruses 12: 861. doi: 10.3390/v12080861
|
[106]
|
Locht C (2020) Vaccines against COVID-19. Anaesth Crit Care Pain Med 39: 703-705. doi: 10.1016/j.accpm.2020.10.006
|
[107]
|
Wagner A, Garner-Spitzer E, Jasinska J, et al. (2018) Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep 8: 9825. doi: 10.1038/s41598-018-28111-8
|
[108]
|
Dugan HL, Henry C, Wilson PC (2020) Aging and influenza vaccine-induced immunity. Cell Immunol 348: 103998. doi: 10.1016/j.cellimm.2019.103998
|
[109]
|
van den Berg SPH, Wong A, Hendriks M, et al. (2018) Negative Effect of Age, but Not of Latent Cytomegalovirus Infection on the Antibody Response to a Novel Influenza Vaccine Strain in Healthy Adults. Front Immunol 9: 82. doi: 10.3389/fimmu.2018.00082
|
[110]
|
Farina SF, Gao GP, Xiang ZQ, et al. (2001) Replication-defective vector based on a chimpanzee adenovirus. J Virol 75: 11603-11613. doi: 10.1128/JVI.75.23.11603-11613.2001
|
[111]
|
Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10: 616-629. doi: 10.1016/j.ymthe.2004.07.013
|
[112]
|
Vogels R, Zuijdgeest D, van Rijnsoever R, et al. (2003) Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77: 8263-8271. doi: 10.1128/JVI.77.15.8263-8271.2003
|
[113]
|
Nidetz NF, McGee MC, Tse LV, et al. (2020) Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacol Ther 207: 107453. doi: 10.1016/j.pharmthera.2019.107453
|
[114]
|
Hinz T, Kallen K, Britten CM, et al. (2017) The European Regulatory Environment of RNA-Based Vaccines. Methods Mol Biol 1499: 203-222. doi: 10.1007/978-1-4939-6481-9_13
|
[115]
|
Plotkin S (2014) History of vaccination. Proc Natl Acad Sci USA 111: 12283-12287. doi: 10.1073/pnas.1400472111
|
[116]
|
Dalmo RA (2018) DNA vaccines for fish: Review and perspectives on correlates of protection. J Fish Dis 41: 1-9. doi: 10.1111/jfd.12727
|
[117]
|
Tanne JH (2020) Covid-19: Pfizer-BioNTech vaccine is rolled out in US. BMJ 371: m4836. doi: 10.1136/bmj.m4836
|
[118]
|
Lundstrom K (2020) Self-Amplifying RNA Viruses as RNA Vaccines. Int J Mol 21: 5130. doi: 10.3390/ijms21145130
|
[119]
|
Broderick KE, Humeau LM (2017) Enhanced Delivery of DNA or RNA Vaccines by Electroporation. Methods Mol Biol 1499: 193-200. doi: 10.1007/978-1-4939-6481-9_12
|
[120]
|
Zheng Z, Diaz-Arévalo D, Guan H, et al. (2018) Noninvasive vaccination against infectious diseases. Hum Vaccin Immunother 14: 1717-1733. doi: 10.1080/21645515.2018.1461296
|
[121]
|
Moderna Moderna's Company History Available from: https://www.modernatx.com/about-us/moderna-facts.
|
[122]
|
Soiza RL, Scicluna C, Thomson EC (2021) Efficacy and safety of COVID-19 vaccines in older people. Age Ageing 50: 279-283. doi: 10.1093/ageing/afaa274
|
[123]
|
Di Pasquale A, Preiss S, Tavares Da Silva F, et al. (2015) Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel) 3: 320-343. doi: 10.3390/vaccines3020320
|
[124]
|
Zepp F (2010) Principles of vaccine design-Lessons from nature. Vaccine 28: C14-C24. doi: 10.1016/j.vaccine.2010.07.020
|
[125]
|
Levin Y, Kochba E, Shukarev G, et al. (2016) A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine 34: 5262-5272. doi: 10.1016/j.vaccine.2016.09.008
|
[126]
|
Del Giudice G, Rappuoli R, Didierlaurent AM (2018) Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol 39: 14-21. doi: 10.1016/j.smim.2018.05.001
|
[127]
|
Mascola JR, Fauci AS (2020) Novel vaccine technologies for the 21st century. Nat Rev Immunol 20: 87-88. doi: 10.1038/s41577-019-0243-3
|
[128]
|
Tregoning JS, Russell RF, Kinnear E (2018) Adjuvanted influenza vaccines. Hum Vaccin Immunother 14: 550-564. doi: 10.1080/21645515.2017.1415684
|
[129]
|
Trucchi C, Paganino C, Orsi A, et al. (2015) Influenza vaccination in the elderly: why are the overall benefits still hotly debated? J Prev Med Hyg 56: E37-E43.
|
[130]
|
Bonmarin I, Belchior E, Lévy-Bruhl D (2015) Impact of influenza vaccination on mortality in the French elderly population during the 2000–2009 period. Vaccine 33: 1099-1101. doi: 10.1016/j.vaccine.2015.01.023
|
[131]
|
Koldaş ZL (2017) Vaccination in the elderly population. Turk Kardiyol Dern Ars 45: 124-127.
|
[132]
|
Rizzo C, Rezza G, Ricciardi W (2018) Strategies in recommending influenza vaccination in Europe and US. Hum Vaccin Immunother 14: 693-698. doi: 10.1080/21645515.2017.1367463
|
[133]
|
Triglav TK, Poljak M (2013) Vaccination indications and limits in the elderly. Acta Dermatovenerol Alp Pannonica Adriat 22: 65-70.
|
[134]
|
Cano Gutierrez C, Reyes-Ortiz C, Borda MG, et al. (2016) Self-reported vaccination in the elderly: SABE Bogota study, Colombia. Colomb Med (Cali) 47: 25-30. doi: 10.25100/cm.v47i1.2107
|
[135]
|
Zeevat F, van der Schans J, Boersma WG, et al. (2019) Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's advice. Vaccine 37: 6282-6284. doi: 10.1016/j.vaccine.2019.08.051
|
[136]
|
Naito T, Yokokawa H, Watanabe A (2018) Impact of the national routine vaccination program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in elderly persons in Japan. J Infect Chemother 24: 496-498. doi: 10.1016/j.jiac.2018.01.004
|
[137]
|
Domínguez A, Soldevila N, Toledo D, et al. (2016) Project Pi12/02079 Working Group. Factors associated with pneumococcal polysaccharide vaccination of the elderly in Spain: A cross-sectional study. Hum Vaccin Immunother 12: 1891-1899.
|
[138]
|
Francisco PM, Borim FS, Neri AL (2015) Vaccination against influenza in the elderly: data from FIBRA, Campinas, São Paulo, Brazil. Cien Saude Colet 20: 3775-3786. doi: 10.1590/1413-812320152012.19702014
|
[139]
|
Forstner C, Kwetkat A, Schleenvoigt B, et al. (2018) Risikoimpfungen im Alter [Vaccinations in the elderly - who, when and which vaccine to use]. MMW Fortschr Med 160: 52-61. doi: 10.1007/s15006-018-0029-8
|
[140]
|
Norton EB (2019) Altered responses to pneumococcal vaccination in an elderly diabetic Japanese vaccine trial: The risk of concurrent vaccination strategies. J Diabetes Complications 33: 189-190. doi: 10.1016/j.jdiacomp.2018.12.007
|
[141]
|
Kajikawa N, Kataoka Y, Goto R, et al. (2019) Factors associated with influenza vaccination in Japanese elderly outpatients. Infect Dis Health 24: 212-221. doi: 10.1016/j.idh.2019.07.002
|
[142]
|
de Boer PT, Pouwels KB, Cox JM, et al. (2013) Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine 31: 1276-1283. doi: 10.1016/j.vaccine.2012.12.067
|
[143]
|
Paccalin M, Weinberger B, Nicolas JF, et al. (2010) The intradermal vaccination route—an attractive opportunity for influenza vaccination in the elderly. Eur Geriatr Med 1: 82-87. doi: 10.1016/j.eurger.2010.03.004
|
[144]
|
Wang J, Peng Y, Xu H, et al. (2020) The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech 21: 225. doi: 10.1208/s12249-020-01744-7
|
[145]
|
Escobar LE, Molina-Cruz A, Barillas-Mury C (2020) BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci USA 117: 17720-17726. doi: 10.1073/pnas.2008410117
|
[146]
|
Kim YC, Park JH, Prausnitz MR (2012) Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 64: 1547-1568. doi: 10.1016/j.addr.2012.04.005
|
[147]
|
Zhang L, Wang W, Wang S (2015) Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines 14: 1509-1523. doi: 10.1586/14760584.2015.1081067
|
[148]
|
Forster AH, Witham K, Depelsenaire ACI, et al. (2020) Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. PLoS Med 17: e1003024. doi: 10.1371/journal.pmed.1003024
|
[149]
|
Rouphael NG, Paine M, Mosley R, et al. (2017) TIV-MNP 2015 Study Group. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet 390: 649-658. doi: 10.1016/S0140-6736(17)30575-5
|
[150]
|
Korkmaz E, Balmert SC, Sumpter TL, et al. (2021) Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Deliv Rev 171: 164-186. doi: 10.1016/j.addr.2021.01.022
|
[151]
|
Nguyen TT, Oh Y, Kim Y, et al. (2021) Progress in microneedle array patch (MAP) for vaccine delivery. Hum Vaccin Immunother 17: 316-327. doi: 10.1080/21645515.2020.1767997
|
[152]
|
Hossain MK, Ahmed T, Bhusal P, et al. (2020) Microneedle Systems for Vaccine Delivery: the story so far. Expert Rev Vaccines 19: 1153-1166. doi: 10.1080/14760584.2020.1874928
|
[153]
|
Weinberger B (2020) Vaccines for Older Adults: Current Practices and Future Opportunities. Interdiscip Top Gerontol Geriatr. Basel Karger 43: VI-IX.
|
[154]
|
Costa R, Castagna A, Ruotolo G (2021) COVID-19 and cardiovascular problems in elderly patients: Food for thought. Aging Med (Milton) 28: 10.1002/agm2.12149.
|
[155]
|
Napoli C, Tritto I, Benincasa G, et al. (2020) Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. Ann Med Surg (Lond) 57: 236-243. doi: 10.1016/j.amsu.2020.07.054
|
[156]
|
O'Neill LAJ, Netea MG (2020) BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol 20: 335-337. doi: 10.1038/s41577-020-0337-y
|
[157]
|
European Commission I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly Available from: https://cordis.europa.eu/project/id/634446.
|
[158]
|
European Centre for Disease Prevention and Control Generic protocol on enhanced surveillance for invasive pneumococcal disease at the EU/EEA level. Stockholm: ECDC Available from: https://www.ecdc.europa.eu/sites/default/files/documents/SpIDnet_Protocol_enhanced_surveillance-2018.pdf.
|
[159]
|
Dirmesropian S, Wood JG, MacIntyre CR, et al. (2016) Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges. Pharmacoeconomics 34: 723-731. doi: 10.1007/s40273-016-0393-0
|
[160]
|
Gilbert SC (2012) T-cell-inducing vaccines—what's the future. Immunology 135: 19-26. doi: 10.1111/j.1365-2567.2011.03517.x
|
[161]
|
Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. (2021) T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 27: 270-278. doi: 10.1038/s41591-020-01194-5
|
[162]
|
van Marum RJ (2020) Underrepresentation of the elderly in clinical trials, time for action. Br J Clin Pharmacol 86: 2014-2016. doi: 10.1111/bcp.14539
|